PPARA and metabolic dysfunction-associated steatohepatitis: In NASH model mice, the PPARα/γ dual agonist saroglitazar and the PPARα/γ/δ triple agonist lanifibranor are effective in protecting the liver from metabolic disorders and fibrosis (Wettstein et al., 2017; Jain et al., 2018).